Selective inhibition of the pacemaker channel I(f) improves symptoms in severe dilated cardiomyopathy.
Hoppe
Uta C
UC
La Rosée
Karl
K
Larbig
Robert
R
Erdmann
Erland
E
D000319:Adrenergic beta-Antagonists; D000368:Aged; D001552:Benzazepines / Q000494:pharmacology / Q000627:therapeutic use*; D002311:Cardiomyopathy, Dilated / Q000150:complications* / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology; D000075202:Contraindications; D018618:Echocardiography, Doppler, Color; D004562:Electrocardiography; D005260:Female; D006329:Heart Conduction System / Q000187:drug effects* / Q000378:metabolism / Q000503:physiopathology; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D000077550:Ivabradine; D009157:Myasthenia Gravis / Q000150:complications*; D026902:Potassium Channel Blockers / Q000494:pharmacology / Q000627:therapeutic use*; D015221:Potassium Channels / Q000187:drug effects* / Q000378:metabolism; D013616:Tachycardia, Sinus / Q000188:drug therapy* / Q000209:etiology / Q000378:metabolism / Q000503:physiopathology; D016896:Treatment Outcome
D000319:Adrenergic beta-Antagonists; D001552:Benzazepines; D026902:Potassium Channel Blockers; D015221:Potassium Channels; D000077550:Ivabradine